This page is updated frequently with new Receptor-related patent applications.
|| List of recent Receptor-related patents
|Printing system and printing instruction apparatus|
A printing instruction apparatus includes, a print data generator that generates first print data corresponding to document data of a first copy in document data and second print data corresponding to document data of second and subsequent copies in the document data, according to a print request for multiple copies of the document data, and a transmitter that transmits the generated first print data to the printing apparatus. A printing apparatus includes, a receptor that receives the transmitted first print data, a printer that performs printing according to the received first print data, and an operator that receives a print execution operation corresponding to a printed result according to the first print data.
|Systems and process for forming carbon nanotube sensors|
A system for forming a functionalized sensor for sensing a molecule of interest includes at least one single or multi-wall carbon nanotube having a first and a second electrode in contact therewith on a substrate; a third electrode including a decorating material on the substrate a predetermined distance from the at least one single or multi-wall carbon nanotube having a first and a second electrode in contact therewith, wherein the decorating material has a bonding affinity for bioreceptors that react with the molecule of interest; and wherein applying a voltage to the third electrode causes the decorating material to form nanoparticles of the decorating material on the at least one single or multi-wall carbon nanotube.. .
The present disclosure relates to a biosensor device for detecting a predetermined target analyte. The device comprises a substrate.
|T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds|
Also the present invention relates to the use of hetero-oligomeric taste receptors comprising t1r1/t1r3 and t1r2/t1r3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli.. .
|Wafer to wafer alignment|
Wafer to wafer alignment which includes a first semiconductor wafer and a second semiconductor wafer. The first and second semiconductor wafers have selectively-activated alignment arrays for aligning the first semiconductor wafer with the second semiconductor wafer.
|System and securing a conductive cable within a wind turbine rotor blade|
The present disclosure is directed to a system and method for securing a lightning protection cable (e.g. A conductor) of a lightning protection system within a wind turbine rotor blade.
|Comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system|
The present disclosure provides comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system by identifying the phenotype of cells and correlating the phenotype with the gene expression profile of the cells, which is indicative of cell function. The cells can be immune cells from a subject suffering from immune-mediated disorders that result in imbalance of the immune system and impair a subject's ability to recognize self-antigens or fight infection or disease.
|Genetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease|
The present disclosure is based on the identification of biomarkers of combined genetic variants and imaging measurements, in predicting faster decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease. The present disclosure provides a method of treating a patient with alzheimer's disease (ad) or a subject susceptible to developing ad, comprising: (a) assaying a sample obtained from an early-stage ad patient or a subject susceptible to developing ad for the presence of a brain-derived neurotrophic factor (bdnf) gene mutation and/or a protein tyrosine phosphatase receptor-type, z polypeptide 1 (ptprz1) gene mutation; (b) determining whether the patient or subject is positive for brain amyloid-beta (aβ), wherein the presence of brain aβ in combination with the bdnf gene and/or ptprz1 gene mutation correlates with a prediction of rapid cognitive decline; and (c) treating the patient or subject with early and aggressive therapy appropriate to treat ad with rapid cognitive decline..
|Methods of inducing and preventing neurofibromatosis in schwann cells|
The invention provides a method of inducing neurofibromatosis type 2 (nf2) in schwann cells. The method comprises contacting the cells with laminin-1 so as to bind α6β1 integrin sufficiently to activate endogenous kinase cdc42-pak; and phosphorylating schwannomin-s518 in the cells by the activated kinase, effectively inactivating.
|Humanized monoclonal antibodies and methods of use|
The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.
Binding molecules for bcma and cd3
The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of bcma, and the second binding domain is capable of binding to the t cell cd3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector.
Prion protein as a receptor for amyloid-beta oligomers
The invention provides methods of inhibiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating alzheimer's disease by administration of a prpc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinations, as well as methods of identifying molecules that could function as prpc antagonists..
Methods and compositions relating to anti-il-21 receptor antibodies
The present invention provides compositions and methods relating to antigen binding proteins against il-21 receptor.. .
Antibodies to tigit
The present invention provides antibodies, or antigen binding fragments thereof, that bind to human tigit (t cell immunoreceptor with ig and itim domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the pd-1/pd-l1 interaction.
Thrombopoietin receptor ligands for neuroprotection
Methods for the treatment of an ischemic event (e.g., stroke) that creates or embodies a risk of neurological damage in cns sites by administration of a thrombopoietin receptor ligand.. .
Oligomeric receptor ligand pair member complexes
This invention concerns an oligomeric receptor-ligand pair member in general and an oligomeric mhc-peptide complex in particular and a method of labeling, detecting and separating mammalian t cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell.
Cd40l collectin fusion proteins
The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.
Mu opioid receptor agonist analogs of the endomorphins
The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated amino acid and (ii) a d-amino acid substitution in position 2.
Bradykinin receptor modulators and use thereof
The present invention relates generally to novel biological and purified peptides as bradykinin receptor modulators for use in the treatment and/or prevention of inflammatory diseases, pain, hyperalgesia, cardiovascular and/or cerebral ischemic diseases, in a subject in need thereof.. .
Peptide for suppressing osteoclast differentiation and use thereof
The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (il)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of nf-κb and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-b ligand (rankl)-rank signaling pathway, and suppresses the expression of a rankl or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (trap), cathepsin k, or tnf receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration.
Melanocortin receptor ligands modified with hydantoin
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.. .
Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
The present invention is directed to the provision of small molecule inhibitors of the psd-95/nmda receptor interaction, employing an undecapeptide corresponding to the c-terminal of the nmda as a template for finding lead candidates. A compound (nmdar/psd-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence ytxv or ysxv, wherein y is selected from among e, q, and a, or an analogue thereof, and x is selected from among a, q, d, n, n-me-a, n-me-q, n-me-d, and n-me-n or an analogue thereof, wherein an amino-terminal residue of the peptide is n-alkylated.
Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents
Are provided. Pharmaceutical compositions comprising either the compound of formula i or formula ii are disclosed.
Oral pharmaceutical compositions of buprenorphine and another opioid receptor agonist
The present invention is directed to oral pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof.. .
Novel hydroximic acid derivative and medical application thereof
The present invention relates to a kind of new hydroximic acid derivatives, in particular, hydroximic acid derivatives of pyrazolopyrimidine and their medical applications, which have inhibition to histone deacetylase 1 and two kinds of tyrosine kinases (vascular endothelial cell growth factor receptors as well as platelet-derived growth factor receptors) simultaneously, and thus can be used for treatment of diseases related to those three kinds of enzymes. This kind of compounds both exerts a synergistic effect sufficiently to increase biological activity, and avoids problems caused by different properties and metabolisms, therefore is more practical and has good prospects..
Spirocyclic ebi2 modulators
Provided herein are small molecule epstein-barr virus-induced g-protein coupled receptor 2 (ebi2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, ebi2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease..
8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
Wherein r1, r2, r3, a, and g are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds..
Wherein x, y, r1, r2, r3, r4 and r5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the cxcr3 receptor.. .
Hydroxy containing fxr (nr1h4) modulating compounds
The present invention relates to compounds which bind to the nr1h4 receptor (fxr) and act as agonists of fxr. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds..
Oxazole orexin receptor antagonists
The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Antagonists of prostaglandin ep3 receptor
Provided herein are antagonists of prostaglandin ep3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.. .
Selectively substituted quinoline compounds
Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (sle) and lupus nephritis.. .
11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
The disclosure includes compounds and pharmaceutically acceptable salts of formula (i). Certain compounds and salts of formula (i) are selective inhibitors of the dopamine d2 receptor.
Novel biphenyl derivative and preparing same
The present invention provides novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, methods for preparing the same, and a pharmaceutical composition containing the same. The novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, as disclosed in the present invention, act as muscarinic m3 receptor antagonists, and thus are useful for the prevention or treatment of a disease selected from the group consisting of chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes..
Combination therapy to promote wound healing
Methods for increasing and/or promoting wound healing, wound re-epithelialization and dermal regeneration of epithelial tissues and cutaneous wounds by administration to a subject of an extracellular matrix scaffold or scaffold for dermal regeneration (sdr) populated with beta adrenergic receptor antagonist pre-conditioned mesenchymal stem cells (mscs) are provided. Compositions and kits comprising an extracellular matrix scaffold (ecms) populated with beta adrenergic receptor antagonist pre-conditioned mesenchymal stem cells (mscs) are also provided..
Drug delivery of temozolomide for systemic based treatment of cancer
The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (tmz) by conjugating tmz in its hydrazide form to a polymalic acid platform.
Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
Methods are provided for administering an extended half-life glp-1/gip coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.. .
Il-13 receptor binding peptides
A targeting peptide that specifically binds to an il13 receptor (e.g., wherein said targeting peptide is not an il13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule.
Chimeric immunoreceptor useful in treating human cancers
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of t lymphocytes, direct t cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific.
Melanotropin ligands for skin care
A melanocortin 1 receptor (mc1r) peptide ligand-elastic vesicle complex. The mc1r peptide ligand is modified by coupling the mc1r ligand to a functionality or linker, such as a click functionality, for conjugation to a surface or agent.
Calcimimetics and methods for their use
Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (pth) levels and calcium levels in patients who undergo hemodialysis.
Compositions and methods for inducing urinary voiding and defecation
Methods, pharmaceutical formulations, and kits are provided for using neurokinin 2 receptor agonists to effectuate voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing voiding of urine and defecation in mammals that do not have a voiding dysfunction such as, for example, in a person who is comatose and may void unconsciously or in a pet at a convenient location at a specific time.
Targeting of herpes simplex virus to specific receptors
The invention relates to engineered herpes simplex virus (hsv) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such hsv particles are provided.
Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof.
Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof.
Methods for controlled activation or elimination of therapeutic cells
The technology relates in part to methods for controlling the activity or elimination of therapeutic cells using multimerization of proteins to manipulate individual protein-protein interactions in therapeutic cells, for example, by activating or eliminating cells used to promote engraftment, to treat diseases or condition, or to control or modulate the activity of therapeutic cells that express chimeric antigen receptors or recombinant t cell receptors.. .
Brain function-improving composition
Provided is a brain function-improving composition which can inhibit binding of homocysteic acid to a receptor (nmda receptor) and, at the same time, decrease the binding ability of homocysteic acid per se to the receptor to thereby improve reduction in the brain function caused by the toxicity of homocysteic acid. The brain function-improving composition comprises 0.3-0.5 part by weight of a cinnamic acid derivative compound and 0.5-0.7 part by weight of a calcium hydride powder.
Compositions, methods and kits for treating cancer
Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ12-prostaglandin j3 or a derivative thereof, or a prostaglandin d receptor (dp) agonist. The compositions may further include a second anti-cancer drug.
According to the invention there is provided a compound of formula a1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the a1-a2b or, particularly, the a2a receptor wherein the compound of formula a1 has the structure, wherein, a represents cy1 or heta; cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which cy1 group is optionally substituted by one or more r4a substituents; heta represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from o, s and n, which heterocyclic group may comprise one, two or three rings and which heta group is optionally substituted by one or more r4b substituents; b represents a cy2 or hetb; cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which cy2 group is optionally substituted by one or more r4c substituents; hetb represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from o, s and n, which heterocyclic group may comprise one or two rings and which heta group is optionally substituted by one or more r4d substituents. .
Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
And stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula i compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..
Selective at2 receptor agonists for use in treatment of cachexia
The present invention is directed to selective at2 receptor agonist or a pharmaceutically acceptable salt thereof for use in treatment of cachexia, preferably for use in treatment of cancer cachexia.. .
Estrogen receptor modulators and uses thereof
And stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..
Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer.
Sphingosine 1 phosphate receptor moduators and their use to treat muscle inflammation
Sip receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.. .
Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics
Provided herein are novel agents that modulate ahr activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise ahr inhibitors or non-constitutive ahr agonists of formula (i) and (ii) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness..
Nmda receptor antagonist formulation with reduced neurotoxicity
The present invention is directed to pharmaceutical compositions of effective amounts of nmda receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity.
Pharmaceutical composition for preventing or treating diabetes mellitus, preventing or treating diabetes mellitus, and screening for diabetes mellitus therapeutic agent
Provided are a pharmaceutical composition including geraniol or a pharmaceutically acceptable salt thereof as an active ingredient for use in preventing or treating diabetes mellitus, a method of preventing or treating diabetes mellitus or a complication due to diabetes mellitus of an individual, in which the method includes administering the individual with a pharmaceutical composition comprising geraniol or a pharmaceutically acceptable salt thereof as an active ingredient and inducing an olfactory stimulation to the individual using the pharmaceutical composition, and a screening method of an antidiabetic agent that may include contacting a cell expressing an olfactory receptor with a test material; measuring a level of expression of glucagon-like peptide-1 (glp-1) secreted from the cell; and determining the test material, when the test material promotes expression of glp-1, as a candidate material of an antidiabetic agent. In addition, a quasi-drug composition and a cosmetic composition including geraniol for uses are provided..
Yeast cell wall particles for receptor-targeted nanoparticle delivery
The present invention generally relates to yeast cell wall microparticles loaded with nanoparticles for receptor-targeted nanoparticle delivery. In particular, the present invention relates to trapping nanoparticles either on the surface or inside a yeast glucan particles, for example, yeast glucal particles.
Ophthalmic apparatus, photoreceptor cell detection method and program
An ophthalmic apparatus includes an image acquiring unit configured to acquire an eye fundus image of an eye to be examined, a candidate acquiring unit configured to acquire a plurality of candidate points for a photoreceptor cell in the eye fundus image based on brightness values of the eye fundus image, a first acquiring unit configured to acquire a first feature value of a first candidate point included in the plurality of candidate points based on a distance between the first candidate point and a second candidate point included in the plurality of candidate points, and a determining unit configured to determine whether the first candidate point is a point representing the photoreceptor cell or not based on the first feature value.. .
A charging system for a battery powered device is described. The system has a battery charger with charging terminals for a battery.
Imaging system with electrophotographic patterning of an image definition material and methods therefor
A system comprises an electrophotographic subsystem, a transfer subsystem, an imaging member, and an inking subsystem. The electrophotographic subsystem comprises a photoreceptor, a charging subsystem, an exposure subsystem, and a development subsystem.
Tracking donor-reactive tcr as a biomarker in transplantation
The invention provides for the use of deep sequencing of the t-cell receptor beta cdr3 to identify, then track donor specific and/or recipient specific t cells in blood, urine and/or end-organs of transplant recipients.. .
Adaptive Biotechnologies Corp.
Detection of analytes using metal nanoparticle probes and dynamic light scattering
Disclosed herein are systems and methods for detecting chemical species, biomolecules and biotargets (analytes) using receptor functionalized metal nanoparticles and dynamic light scattering.. .
University Of Central Florida Research Foundation, Inc.
Label-free detection of small and large molecule interactions, and activities in biological systems
A system for quantitative detection and analysis of the interactions of molecules with molecular receptors on the surfaces of biological cells based on detecting a mechanical deformation in the membrane of a cell associated with the molecular interactions, which works for both large and small molecules. The mechanical deformation can be detected with high precision in real time from an optical image of the cell with a differential detection method.
Arizona Board Of Regents On Behalf Of Arizona State University
Method for predicting response to breast cancer therapeutic agents and treatment of breast cancer
Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.. .
Medivation Prostate Therapeutics, Inc.
Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and methods for preparing the composition and stimulating immune response thereby
Cpg-oligodeoxynucleotides (cpg-odn), as potent immune stimuli developed for using as adjuvant in different species, are disclosed herein. Tlr9 is the cellular receptor for cpg-odn, and current developed cpg-odn has low activity to rabbit tlr9.
National Health Research Institutes
Anti-immunoglobulin e antibodies and methods of using thereof
The present disclosure provides antibodies that specifically bind to circulating and receptor-bound ige and inhibit ige-mediated cell activation. The antibodies find use in various treatment, diagnostic, and monitoring applications, which are also provided..
Monoclonal antibody and a method thereof
The present invention relates to a humanized igg1 isotype anti-cd6 antibody (t1h) that binds to the scavenger receptor cysteine-rich (srcr) domain 1 (d1) of cd6 present on the surface of thymic epithelial cells, monocytes, activated t cells and a variety of other cells types.. .
Bag3 receptor binding molecules for use as a medicament
The present invention relates to the use of bag3 receptor-binding molecules as a medicament, in particular for use in the treatment of diseases of an immune, inflammatory, cardiovascular, neoplastic and/or degenerative nature.. .
Therapeutic fusion protein
The invention relates to a fusion protein comprising an antibody directed to aβ, a monovalent binding entity which binds to a blood brain barrier receptor and a neprilysin.. .
Hoffmann- La Roche Inc.
Antibodies for guanylyl cyclase receptors
Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.. .
Method for treating tumors that possess the cck-c receptor with the 3b9.1 monoclonal antibody
Human pancreatic cancer cells possess a distinct plasma membrane cck receptor variant that can be differentiated from the classic cck-b receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer..
Trpm4 channel inhibitors for stroke treatment
The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting the transient receptor potential melastatin 4 (trpm4) channel.
Singapore Health Services Pte Ltd
Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
The present invention relates to methods for treating and preventing staphylococcus aureus infection and/or a condition resulting from a s. Aureus infection in a subject that involves administering compositions that inhibit s.
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. .
Methods and compositions for the treatment of gastrointestinal disorders
Compositions and related methods for treating ibs and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (gerd), duodenogastric reflux, crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase c (gc-c) receptor..
Ironwood Pharmaceuticals, Inc.
Conjugates containing hydrophilic spacer linkers
Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.. .
Genetically-modified zebrafish lacking one or more immune-related genes, and the use thereof, e.g., in cell or tissue transplantation methods or in stem cell biology. In a first aspect, the invention provides a genetically-modified fish whose genome is homozygous for engineered or induced genetic alteration, e.g., an alteration that changes the sequence of the genomic ona resulting in insertion and deletion of nucleotides that disrupt protein function or shift the frame of translation leading to premature protein termination, in one or more immune-related genes selected from the group consisting of: foxn1, rag2, jak3, prkdc, and interleukin 2-receptor gamma a and (il2rga and il2rgb),wherein the genetic alteration results in an inactivation (i.e., loss of expression or function) of both alleles of the immune-related gene..
The General Hospital Corporation
Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent.
Toll-like receptor agonists
Compounds described herein can be used for therapeutic purposes. The compounds can be tlr agonists, such as tlr7 or tlr8 agonists.
Antigenic compositions and methods
Multilayer films comprised of polypeptide epitopes and a toll-like receptor ligand. The multilayer films are capable of eliciting an immune response in a host upon administration to the host.
Artificial Cell Technologies, Inc.
Divalent vaccine compositions and the use thereof for treating tumors
The invention describes vaccine compositions combined in the same proportion with the extracellular domains of growth factor receptors her1 and her2 or fragments thereof and furthermore very small size proteoliposomes derived from proteins of the outer membrane of neisseria meningitidis and gm3 ganglioside (vssp-gm3), administered subcutaneously. The disclosed compositions, which induce the production of antibodies are used for the treatment of malignancies and offer advantages because they completely remove the tumor mass thus preventing tumor regression due to the emergence of resistant variants..
Centro De Inmunologia Molecular
Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (pacap) which can both agonize pac1 receptors, causing neuroprotective effects, and antagonize vpac receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including als, pd, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of als, pd, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated pacap..
The Arizona Board Of Regents On Behalf Of The University Of Arizona
Bioconjugates of synthetic apelin polypeptides
Or an amide, an ester or a salt thereof, wherein x1, x2, x3, x4, x5, x6, x7, x8, x9, x10, x11, x12 and x13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the apj receptor.
Treatment of retinal degeneration using progenitor cells
Methods and compositions for treating and reducing retinal degeneration using progenitor cells and conditioned media from progenitor cells, such as postpartum-derived cells are disclosed. Trophic factors and other agents secreted by the progenitor cells that protect retinal cells and inhibit apoptosis of retinal cells such as photoreceptor cells are also disclosed..
Janssen Biotech, Inc.
Methods for controlled elimination of therapeutic cells
The technology relates in part to methods for controlling elimination of therapeutic cells, for example, cells that express a chimeric antigen receptor. The technology further relates to a two-step method of controlling destruction of therapeutic cells in a patient following an adverse event.
Bellicum Pharmaceuticals, Inc.
A treating infection, sepsis and injury
The invention relates to a composition or method for treating at least one of infection, sepsis and injury or inducing a hypotensive state or a low pain or analgesic state in a subject susceptible to or suffering from at least one of infection, sepsis and injury. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; and (ii) an antiarrhythmic agent or a local anaesthetic..
Hibernation Therapeutics, A Kf Llc
Compositions and methods to treat cardiac diseases
Phosphonate and phosphinate n-methanocarba derivatives of amp including their prodrug analogs are described. Mrs2339, a 2-chloro-amp derivative containing a (n)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates p2x receptors, ligand-gated ion channels.
The United States Of America As Represented By The Secretary Department Of Health And Human Services
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
This invention relates to amidopyrazole compounds that are inhibitors of interieukin receptor-associated kinases, in particular irak-4, and are useful in the treatment of cellular proliferative diseases. Speifically (5-methylpyridin-2-yl)-1 h-pyrazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives are disclosed for use in the method of treating inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and cancer..
Merck Sharp & Dohme Corp.
Method for treating skin thickening
Methods, compositions and products for treating or reducing skin thickening in a subject are described. Also described are methods of inhibiting a skin disorder induced by an uv-irradiation.
Galderma Research And Development
Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1h)-one derivatives having both muscarinic receptor antagonist and beta2 adrenergic receptor agonist activities
The present invention is directed to crystalline addition salts of (ii) 8-hydroxyquinolin-2(1h)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.. .
Antipsychotic treatment based on drd2 or ankk1 snp genotype
The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (snp) associated with the dopamine receptor d2 (drd2) and/or ankyrin repeat and kinase domain containing 1 (ankk1) genes.. .
Vanda Pharmaceuticals, Inc.
Screening methods for identifying compounds and compounds and pharmaceutical compositions for treating and preventing cancer are disclosed. The compounds affect signal transduction downstream of the met receptor..
Brigham Young University
Selective androgen receptor modulator and methods of use thereof
This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as duchenne muscular dystrophy or becker muscular dystrophy.. .
University Of Tennessee Research Foundation
Nasal drug products and methods of their use
Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided..
Lightlake Therapeutics, Inc.
X ray apparatus and operating the same
An x-ray apparatus which aligns an x-ray radiator with an x-ray detector, an x-ray apparatus which aligns an x-ray radiator with an x-ray detector while maintaining a source to image-receptor distance (sid) and a source to object distance (sod) therebetween, and methods of operating the x-ray apparatuses are provided.. .
Samsung Electronics Co., Ltd.
A shower receptor includes a generally planar base surface, a deck surface, and a threshold surface. The generally planar base surface includes a drain opening.